Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Optimal Sampling and Limited Sampling Strategies for Estimation of Unbound Platinum AUC After Nedaplatin Infusion

TORU ISHIBASHI, KAZUYA FUKUMURA, YOSHITAKA YANO and TAKAYOSHI OGUMA
Anticancer Research March 2005, 25 (2B) 1283-1289;
TORU ISHIBASHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: toru.ishibashi@shionogi.co.jp
KAZUYA FUKUMURA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHITAKA YANO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAYOSHI OGUMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The aim of this study was to determine the optimal sampling design for empirical Bayesian forecasting for nedaplatin, and also to develop a simple formula for estimating the area under the plasma concentration-time curve (AUC) of platinum which relates to hematological toxicity after nedaplatin dosing using limited sampling points. Plasma unbound platinum concentration data were retrospectively collected from 27 courses administered to 20 Japanese adult patients. To determine the optimal sampling points, 1 - 5 data point(s) were selected with all combinations and clearance in each patient was estimated by the empirical Bayesian method. As measures for the Bayesian predictive performance, mean prediction error and root mean squared error were estimated. These indices suggested that the sampling time(s) of 4 hours in case of the one-point sampling gives better estimates for individual clearance. As for the limited sampling strategy, a simple formula to calculate AUC, AUC = 0.039 x dose + 11.6 x Cp4h - 0.88, was obtained, where Cp4h is the concentration at 4 hours after the end of infusin. These results should be helpful for adjusting dosage to achieve the target AUC.

  • Pharmacokinetics
  • pharmacodynamics
  • nedaplatin
  • AUC
  • optimal sampling
  • limited sampling
  • platelet

Footnotes

  • Received July 26, 2004.
  • Accepted December 29, 2004.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (2B)
Anticancer Research
Vol. 25, Issue 2B
1 Mar 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Optimal Sampling and Limited Sampling Strategies for Estimation of Unbound Platinum AUC After Nedaplatin Infusion
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Optimal Sampling and Limited Sampling Strategies for Estimation of Unbound Platinum AUC After Nedaplatin Infusion
TORU ISHIBASHI, KAZUYA FUKUMURA, YOSHITAKA YANO, TAKAYOSHI OGUMA
Anticancer Research Mar 2005, 25 (2B) 1283-1289;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Optimal Sampling and Limited Sampling Strategies for Estimation of Unbound Platinum AUC After Nedaplatin Infusion
TORU ISHIBASHI, KAZUYA FUKUMURA, YOSHITAKA YANO, TAKAYOSHI OGUMA
Anticancer Research Mar 2005, 25 (2B) 1283-1289;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Pelvic Recurrence After Curative Resection for Rectal Adenocarcinoma: Impact of Surgery on Survival
  • Glasgow Prognostic Score Predicts Survival and Recurrence Pattern in Patients With Hepatocellular Carcinoma After Hepatectomy
  • Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire